Aims: The aim of this trial was to investigate the efficacy and tolerability of DCS in treatment of numbing and avoidance in chronic PTSD.
Setting and Design: This was an 11-week, double-blind, randomized, placebo-controlled, cross-over clinical trial conducted in out-patient psychiatry clinics affiliated to Isfahan University of Medical Sciences (IUMS).
Methods and Material: Inclusion criteria included:Male; age 16-65 years; Being Registered as outpatient chronic combat-related PTSD (based on DSM-IV-TR)in outpatient psychaitry clinicsaffiliated to Isfahan University of Medical Sciences (IUMS). were screened for eligibility (n=319). Exclusion criteria included: comorbid psychiatric condition; comorbid severe medical condition; abnormal physical examination or paraclinical test results. 319 patients were screened. The study sample included 76 subjects who were randomly assigned to two groups (n=38). Patients entered a one-week run-in period. Then, the groups received either an add-on treatment of DCS (50 mg daily), or placebo (4 weeks). After a two-week washout, the groups received cross-over treatments (4 weeks). Clinical interview, Clinician Administered PTSD Scale (CAPS), and clinical/paraclinical assessments were performed at baseline, and at the end of the 1st, 5th, 7th and 11th weeks. Side effects were also evaluatedthrough patient reported side effect questionnaire.